Trial Profile

Pharmacology of TDF-FTC Pre-exposure Prophylaxis in Kenyan Cisgender Women

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
Indications HIV infections
Focus Adverse reactions; Pharmacokinetics
Acronyms The Women TDF-FTC Benchmark Study

Most Recent Events

15 Jun 2026 Protocol has been amended to include one new arm (Experimental: Pregnant) , it has changed from 3 to 4.
15 Jun 2026 Status changed from active, no longer recruiting to completed.
08 Aug 2024 Planned primary completion date changed from 31 Mar 2024 to 31 Mar 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com